Coagadex Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to identification of factor ix deficiency, approval of recombinant clotting factors, hemophilia treatment center expansion, improved bleeding management protocols, patient survival improvements.

The growth in the forecast period can be attributed to growth in rare bleeding disorder diagnosis, wider home infusion adoption, improved reimbursement coverage, emerging market access expansion, advancements in recombinant technology. Major trends in the forecast period include rising adoption of recombinant clotting factors, expansion of rare bleeding disorder treatment, shift toward home based hemophilia care, improved access to factor replacement therapy, focus on prophylactic bleeding management.

The rising prevalence of rare bleeding disorders is expected to drive the growth of the Coagadex market in the coming years. Rare bleeding disorders are a group of uncommon conditions that compromise the blood’s ability to clot, resulting in excessive bleeding or difficulty stopping bleeding after injury. This increasing prevalence is influenced by factors such as improved diagnostic capabilities, greater awareness, enhanced healthcare access, and genetic predispositions. Coagadex is used to treat rare bleeding disorders like hereditary Factor X deficiency by replacing the missing clotting factor, effectively managing bleeding episodes. For example, a report published in December 2023 by the United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) for 2023/24 highlights the burden of bleeding disorders, documenting 6,835 individuals with haemophilia A, 1,378 with haemophilia B, alongside 1,845 haemophilia A carriers, 892 females with factor VIII deficiency, and 390 haemophilia B carriers. Consequently, the growing prevalence of rare bleeding disorders has fueled the expansion of the Coagadex market.

A major trend in the Coagadex market is the development of innovative therapies, such as treatments for factor X deficiency, which aim to restore clotting function and reduce the risk of life-threatening bleeding episodes. Factor X deficiency treatments are designed to replace or activate factor X, a vital clotting factor, to prevent or manage bleeding in individuals with this rare genetic condition. For instance, in May 2024, Bio Products Laboratory (BPL), a UK-based pharmaceutical company, received orphan drug marketing authorization for Coagadex in Mexico. Coagadex is the first and only therapy specifically developed for hereditary factor X deficiency, a rare genetic disorder that impairs blood clotting due to insufficient factor X levels. Patients with this condition face severe, potentially life-threatening bleeding episodes. This approval is particularly important for Mexico, where epidemiological data on ultra-rare bleeding disorders are limited and awareness among healthcare professionals is low.

In October 2025, Farma Mondo UAB, a Lithuania-based provider of pharmaceutical market access and specialty distribution services, partnered with Kedrion Biopharma to exclusively distribute Coagadex across Estonia, Latvia, and Lithuania. Through this collaboration, Farma Mondo aims to expand Kedrion’s commercial presence in the Baltic markets and improve patient access to this rare-disease coagulation therapy. Kedrion Biopharma, based in Italy, collects plasma and produces plasma-derived therapies, including coagulation factors like Coagadex, immunoglobulins, and other treatments for rare disorders.

Major companies operating in the coagadex market are Bio Products Laboratory Limited.

North America was the largest region in the coagadex market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the coagadex market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the coagadex market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the coagadex market by raising costs for recombinant protein manufacturing inputs and sterile injectable packaging. These effects are most apparent in hospital pharmacies and specialty hemophilia centers across europe and asia pacific. Import duties have contributed to higher treatment costs for rare bleeding disorders. Distribution efficiency has also been influenced by customs and regulatory requirements. However, tariffs are supporting local biologics production and improving supply chain resilience for clotting factor therapies.

The coagadex market research report is one of a series of new reports that provides coagadex market statistics, including coagadex industry global market size, regional shares, competitors with a coagadex market share, detailed coagadex market segments, market trends and opportunities, and any further data you may need to thrive in the coagadex industry. This coagadex market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Coagadex is a medication used to treat a rare bleeding disorder called hemophilia B. It contains recombinant coagulation factor IX, a clotting factor that helps manage bleeding. Individuals with hemophilia B lack or have insufficient factor IX, which is essential for proper blood clotting. Coagadex replaces this missing factor, helping to prevent and control bleeding episodes, and is usually administered via intravenous (IV) injection.

Coagadex is primarily indicated for hereditary factor X deficiency and other coagulation disorders. Hereditary factor X deficiency is a rare genetic condition caused by insufficient or defective factor X, a vital protein for blood clotting. The medication is distributed through channels including direct sales, pharmaceutical wholesalers, online pharmacies, and retail pharmacies, and is utilized in hospitals, clinics, homecare, and ambulatory surgical centers.

The coagadex market consists of sales of factor IX concentrates, factor VIII concentrates, and monoclonal antibodies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.